Pfizer (PFE) Tax Provisions (2009 - 2026)

Pfizer (PFE) has 18 years of Tax Provisions data on file, last reported at $461.0 million in Q1 2026.

• Quarterly Tax Provisions rose 343.92% year-over-year to $461.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $384.0 million (up 88.24% YoY) and the FY2025 annual result came in at -$266.0 million, down 850.0% from the prior year.
• Tax Provisions climbed to $461.0 million in Q1 2026 per PFE's latest filing, from -$2.0 million in the prior quarter.
• Across five years, Tax Provisions topped out at $1.6 billion in Q3 2022 and bottomed at -$964.0 million in Q4 2023.
• The 5-year median for Tax Provisions is $141.0 million (2025), against an average of $172.4 million.
• The widest annual swing landed in 2023, when Tax Provisions plunged 370.79%; it then surged 343.92% in 2026.
• Tracing PFE's Tax Provisions over 5 years: stood at $356.0 million in 2022, then plunged by 319.1% to -$780.0 million in 2023, then jumped by 130.0% to $234.0 million in 2024, then sank by 100.85% to -$2.0 million in 2025, then jumped by 23150.0% to $461.0 million in 2026.
• Per Business Quant, the three latest PFE Tax Provisions figures stand at $461.0 million (Q1 2026), -$2.0 million (Q4 2025), and -$216.0 million (Q3 2025).

Peer Comparison